Showing 1 - 10 results of 10 for search 'Ingeborg A. Hauser', query time: 0.05s Refine Results
  1. 1
    Isolation, Characterization, Differentiation and Immunomodulatory Capacity of Mesenchymal Stromal/Stem Cells from Human Perirenal Adipose Tissue

    Isolation, Characterization, Differentiation and Immunomodulatory Capacity of Mesenchymal Stromal/Stem Cells from Human Perirenal Adipose Tissue by Patrick C. Baer, Benjamin Koch, Elena Hickmann, Ralf Schubert, Jindrich Cinatl, Ingeborg A. Hauser, Helmut Geiger

    Published 2019-10-01
    Get full text
    Article
  2. 2
    No association of genetic variants in TLR4, TNF-α, IL10, IFN-γ, and IL37 in cytomegalovirus-positive renal allograft recipients with active CMV infection-Subanalysis of the prospective randomised VIPP study.

    No association of genetic variants in TLR4, TNF-α, IL10, IFN-γ, and IL37 in cytomegalovirus-positive renal allograft recipients with active CMV infection-Subanalysis of the prospec... by Pascale Mazzola, Elke Schaeffeler, Oliver Witzke, Martin Nitschke, Volker Kliem, Max Zortel, Eva-Maria Wagner, Matthias Schwab, Ingeborg A Hauser

    Published 2021-01-01
    Get full text
    Article
  3. 3
    Riding the Omicron BA.5 Wave: Improved Humoral Response after Vaccination with Bivalent Omicron BA.4-5-Adapted mRNA SARS-CoV-2 Vaccine in Chronic Hemodialysis Patients

    Riding the Omicron BA.5 Wave: Improved Humoral Response after Vaccination with Bivalent Omicron BA.4-5-Adapted mRNA SARS-CoV-2 Vaccine in Chronic Hemodialysis Patients by Eugen Ovcar, Sammy Patyna, Niko Kohmer, Elisabeth Heckel-Kratz, Sandra Ciesek, Holger F. Rabenau, Ingeborg A. Hauser, Kirsten de Groot

    Published 2023-08-01
    Get full text
    Article
  4. 4
    Everolimus plus reduced calcineurin inhibitor prevents de novo anti-HLA antibodies and humoral rejection in kidney transplant recipients: 12-month results from the ATHENA study

    Everolimus plus reduced calcineurin inhibitor prevents de novo anti-HLA antibodies and humoral rejection in kidney transplant recipients: 12-month results from the ATHENA study by Wolfgang Arns, Aurélie Philippe, Aurélie Philippe, Vanessa Ditt, Ingeborg A. Hauser, Friedrich Thaiss, Claudia Sommerer, Barbara Suwelack, Duska Dragun, Jan Hillen, Christiane Schiedel, Anja Elsässer, Björn Nashan, Björn Nashan

    Published 2023-10-01
    Get full text
    Article
  5. 5
    Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response

    Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response by Sammy Patyna, Timon Eckes, Benjamin F. Koch, Stephan Sudowe, Anke Oftring, Niko Kohmer, Holger F. Rabenau, Sandra Ciesek, Despina Avaniadi, Rahel Steiner, Ingeborg A. Hauser, Josef M. Pfeilschifter, Christoph Betz

    Published 2022-04-01
    Get full text
    Article
  6. 6
    Impact of everolimus plus calcineurin inhibitor on formation of non-HLA antibodies and graft outcomes in kidney transplant recipients: 12-month results from the ATHENA substudy

    Impact of everolimus plus calcineurin inhibitor on formation of non-HLA antibodies and graft outcomes in kidney transplant recipients: 12-month results from the ATHENA substudy by Aurélie Philippe, Aurélie Philippe, Wolfgang Arns, Vanessa Ditt, Ingeborg A. Hauser, Friedrich Thaiss, Claudia Sommerer, Barbara Suwelack, Duska Dragun, Duska Dragun, Jan Hillen, Christiane Schiedel, Anja Elsässer, Björn Nashan, Björn Nashan

    Published 2023-11-01
    Get full text
    Article
  7. 7
    Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study

    Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study by Ute Eisenberger, Klemens Budde, Frank Lehner, Claudia Sommerer, Petra Reinke, Oliver Witzke, Rudolf P. Wüthrich, Rolf Stahl, Katharina Heller, Barbara Suwelack, Anja Mühlfeld, Ingeborg A. Hauser, Silvio Nadalin, Martina Porstner, Wolfgang Arns, on behalf of the ZEUS Study Investigators

    Published 2018-06-01
    Get full text
    Article
  8. 8
    Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials

    Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials by Claudia Sommerer, Oliver Witzke, Frank Lehner, Wolfgang Arns, Petra Reinke, Ute Eisenberger, Bruno Vogt, Katharina Heller, Johannes Jacobi, Markus Guba, Rolf Stahl, Ingeborg A. Hauser, Volker Kliem, Rudolf P. Wüthrich, Anja Mühlfeld, Barbara Suwelack, Michael Duerr, Eva-Maria Paulus, Martin Zeier, Martina Porstner, Klemens Budde, on behalf of the ZEUS and HERAKLES study investigators

    Published 2018-09-01
    Get full text
    Article
  9. 9
    Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial

    Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 St... by Lei Wang, Arianeb Mehrabi, Maria-Luisa Schubert, Anita Schmitt, Brigitte Neuber, Alexander Kunz, Angela Hückelhoven-Krauss, Carsten Müller-Tidow, Michael Schmitt, Christian Morath, Martin Zeier, Constantin Schwab, Anja Sander, Sabine Scherer, Claudius Speer, Christian Kleist, Claudia Sommerer, Florian Kälble, Christian Nusshag, Matthias Schaier, Louise Benning, Vedat Schwenger, Caner Süsal, Gerhard Opelz, T. Hien Tran, Stephan Kemmner, Michael Fischereder, Manfred Stangl, Ingeborg A. Hauser, Christian Bischofs, Sandra Sauer, Rüdiger Waldherr, Christopher Büsch, David Czock, Georg A Böhmig, Jochen Reiser, Axel Roers, Peter Terness, Volker Daniel

    Published 2022-11-01
    Get full text
    Article
  10. 10
    Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation

    Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation by Matthias Schaier, Matthias Schaier, Christian Morath, Christian Morath, Christian Morath, Lei Wang, Lei Wang, Christian Kleist, Christian Kleist, Gerhard Opelz, Thuong Hien Tran, Sabine Scherer, Lien Pham, Naruemol Ekpoom, Caner Süsal, Caner Süsal, Gerald Ponath, Gerald Ponath, Florian Kälble, Claudius Speer, Louise Benning, Christian Nusshag, Christoph F. Mahler, Luiza Pego da Silva, Claudia Sommerer, Claudia Sommerer, Angela Hückelhoven-Krauss, David Czock, Arianeb Mehrabi, Constantin Schwab, Rüdiger Waldherr, Paul Schnitzler, Uta Merle, Vedat Schwenger, Markus Krautter, Stephan Kemmner, Michael Fischereder, Manfred Stangl, Ingeborg A. Hauser, Anna-Isabelle Kälsch, Bernhard K. Krämer, Georg A. Böhmig, Carsten Müller-Tidow, Jochen Reiser, Martin Zeier, Michael Schmitt, Peter Terness, Anita Schmitt, Anita Schmitt, Volker Daniel

    Published 2023-07-01
    Get full text
    Article

Search Tools: